This page maps neurodegenerative diseases to the brain regions they primarily affect, providing a comprehensive reference for understanding regional vulnerability in Alzheimer's disease, Parkinson's disease, and related disorders. Understanding which brain regions are affected by each disease is fundamental to comprehending clinical presentations, disease progression patterns, and the development of targeted therapies. [1]
Neurodegenerative diseases exhibit characteristic patterns of regional brain involvement that distinguish them from one another and contribute to their unique clinical phenotypes. These patterns reflect the underlying molecular pathology and spread of disease through anatomically connected neural networks. This mapping provides a quick reference for researchers, clinicians, and students seeking to understand the neuroanatomical basis of neurodegenerative disease. [2]
--- [3]
Alzheimer's disease (AD) follows a characteristic pattern of progression that begins in limbic structures and spreads to cortical regions. Understanding this sequential involvement is crucial for early diagnosis and intervention. [4]
The entorhinal cortex and hippocampus are the first regions affected in Alzheimer's disease, accounting for the early memory deficits that characterize the condition. The entorhinal cortex serves as the major gateway between the hippocampus and neocortex, and its degeneration disrupts memory consolidation. The hippocampus, critical for forming new memories, shows early tau pathology in the CA1 region and subiculum. [5]
The amygdala is involved early in AD, contributing to emotional dysregulation and the psychological and behavioral symptoms of dementia. Amyloid and tau pathology accumulate in the amygdala alongside hippocampal involvement. [6]
As AD progresses, involvement extends to the temporal lobe regions beyond the hippocampus, including the parahippocampal gyrus and inferior temporal cortex. This progression correlates with worsening memory deficits and the emergence of language difficulties.
The cingulate cortex shows metabolic decline and structural atrophy in moderate AD, contributing to apathy and behavioral changes. The anterior cingulate is particularly vulnerable.
In advanced AD, the disease spreads to frontal lobes and parietal lobes, producing the global cognitive impairment seen in later stages. The prefrontal cortex involvement contributes to executive dysfunction, while parietal lobe damage produces visuospatial deficits.
Parkinson's disease primarily affects subcortical structures, with the characteristic motor symptoms reflecting degeneration of specific nuclei and their connections.
The substantia nigra pars compacta is the hallmark region affected in Parkinson's disease, with loss of dopaminergic neurons producing the motor symptoms of tremor, bradykinesia, and rigidity. The ventral tegmental area, adjacent to the substantia nigra, is also affected, contributing to non-motor symptoms.
The locus coeruleus (noradrenergic) and raphe nuclei (serotonergic) are affected early in PD, contributing to depression, sleep disorders, and autonomic dysfunction. The dorsal motor nucleus of the vagus shows Lewy body pathology even before motor symptoms appear.
The striatum (caudate nucleus and putamen) shows dopaminergic denervation in PD, underlying the motor deficits. The globus pallidus and subthalamic nucleus become dysfunctional as the disease progresses, contributing to motor fluctuations and dyskinesias with long-term levodopa treatment.
In Parkinson's disease with dementia (PDD), cortical regions become involved, particularly the temporal lobe and prefrontal cortex, producing the cognitive decline characteristic of PDD. The pattern resembles diffuse Lewy body disease.
Dementia with Lewy bodies (DLB) shows a distinctive pattern of brain involvement that differentiates it from both AD and PD.
The substantia nigra is affected, though less severely than in PD. The locus coeruleus and raphe nuclei show significant Lewy body pathology.
The temporal lobe, particularly the amygdala and hippocampus, shows Lewy body pathology. The occipital cortex is notably affected, contributing to the visual hallucinations characteristic of DLB. The frontal cortex involvement produces executive dysfunction.
Frontotemporal dementia (FTD) encompasses a group of disorders characterized by selective frontal and/or temporal lobe degeneration.
The prefrontal cortex and anterior cingulate cortex are primarily affected in behavioral variant FTD, producing the characteristic personality changes, disinhibition, and executive dysfunction. The orbitofrontal cortex involvement contributes to impaired decision-making.
The left temporal lobe and frontal operculum are primarily affected in semantic variant PPA, while the left perisylvian cortex is affected in nonfluent/agrammatic variant. The temporal pole shows early involvement in semantic variant.
Corticobasal degeneration shows asymmetric involvement of the prefrontal cortex, parietal cortex, and basal ganglia, producing the characteristic asymmetric motor symptoms and cortical sensory loss.
Progressive supranuclear palsy (PSP) primarily affects subcortical structures and the frontal lobe.
The midbrain (particularly the colliculi), pons, and medulla show degeneration. The superior colliculus is especially affected, producing the vertical gaze palsy characteristic of PSP.
The globus pallidus, subthalamic nucleus, and striatum are involved, contributing to the parkinsonism and axial symptoms. The red nucleus and dentate nucleus of the cerebellum are also affected.
The prefrontal cortex and motor cortex show involvement in later stages, contributing to cognitive decline and motor symptoms.
Huntington's disease produces a characteristic pattern of striatal degeneration that spreads to cortex.
The caudate nucleus and putamen show early and severe degeneration, with medium spiny neurons particularly affected. The striatum shows the characteristic neuron loss and gliosis.
As HD progresses, the cerebral cortex shows degeneration, particularly in frontal and temporal regions, contributing to cognitive and behavioral symptoms.
The globus pallidus, thalamus, and subthalamic nucleus are involved. The hippocampus shows pathology contributing to memory deficits.
Amyotrophic lateral sclerosis (ALS) affects both upper and lower motor neurons.
The motor cortex shows degeneration of upper motor neurons, with corticospinal tract degeneration.
The hypoglossal nucleus, facial nucleus, and ventral horn of the spinal cord show lower motor neuron loss. The bulbar nuclei involvement produces bulbar symptoms.
Frontotemporal involvement occurs in ALS with cognitive impairment, with the prefrontal cortex showing degeneration in some patients.
Multiple system atrophy (MSA) affects multiple brain regions, producing the characteristic autonomic failure and motor symptoms.
The striatum (caudate and putamen) shows severe degeneration, particularly in the putamen. The globus pallidus is also affected.
The pontine nuclei, inferior olivary nucleus, and cerebellar cortex are affected, producing the cerebellar ataxia in MSA-C. The locus coeruleus and raphe nuclei show pathology.
The autonomic nuclei in the spinal cord are affected, contributing to autonomic dysfunction.
| Disease | Primary Regions | Secondary Regions |
|---|---|---|
| Alzheimer's Disease | Hippocampus, Entorhinal Cortex | Temporal Lobe, Frontal Cortex, Parietal Lobe |
| Parkinson's Disease | Substantia Nigra, Striatum | Locus Coeruleus, Brainstem Nuclei |
| Dementia with Lewy Bodies | Temporal Cortex, Occipital Cortex | Substantia Nigra, Frontal Cortex |
| Frontotemporal Dementia | Frontal Cortex, Temporal Lobe | Anterior Cingulate, Orbitofrontal |
| Progressive Supranuclear Palsy | Midbrain, Globus Pallidus | Subthalamic Nucleus, Frontal Cortex |
| Huntington's Disease | Caudate Nucleus, Putamen | Cortex, Thalamus |
| Amyotrophic Lateral Sclerosis | Motor Cortex, Ventral Horn | Brainstem Nuclei, Frontal Cortex |
| Multiple System Atrophy | Striatum, Pons | Cerebellum, Inferior Olivary Nucleus |
Links verified: 2026-03-16
Braak et al. Staging of Alzheimer disease-associated neurofibrillary pathology (2003). 2003. ↩︎
McKeith et al. Diagnosis and management of dementia with Lewy bodies (2017). 2017. ↩︎
Rascovsky et al. Diagnostic criteria for behavioral variant frontotemporal dementia (2011). 2011. ↩︎
Höglinger et al. Clinical diagnosis of progressive supranuclear palsy (2017). 2017. ↩︎